(Q50556485)

English

The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.

scientific article published on 7 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

0 references

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

author name string

Tsugiko Oze

1

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Naoki Hiramatsu

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Takayuki Yakushijin

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Kiyoshi Mochizuki

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Kazuho Imanaka

5

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Akira Yamada

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Masahide Oshita

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Akira Kaneko

8

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Hideki Hagiwara

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Eiji Mita

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Toshifumi Ito

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Toshihiko Nagase

12

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Yoshiaki Inui

13

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Taizo Hijioka

14

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Shinji Tamura

15

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Harumasa Yoshihara

16

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Eijiro Hayashi

17

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Yasuharu Imai

18

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Michio Kato

19

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Atsushi Hosui

20

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Takuya Miyagi

21

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Yuichi Yoshida

22

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Hisashi Ishida

23

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Tomohide Tatsumi

24

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Shinichi Kiso

25

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Tatsuya Kanto

26

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Akinori Kasahara

27

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Tetsuo Takehara

28

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Norio Hayashi

29

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

publication date

7 May 2011

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Journal of Gastroenterology

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

46

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

944-952

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Antiviral therapy for chronic hepatitis C: past, present, and future

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0403-0

21 January 2018

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21552988

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-011-0403-0

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21552988

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50556485&oldid=1562860852"